Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;24(5):1165-1173.
doi: 10.1245/s10434-016-5717-y. Epub 2016 Dec 22.

Use of Tumor Markers in Gastrointestinal Cancers: Surgeon Perceptions and Cost-Benefit Trade-Off Analysis

Amish Acharya  1 , Sheraz R Markar  1 , Michael Matar  1 , Melody Ni  1 , George B Hanna  2
Affiliations

Use of Tumor Markers in Gastrointestinal Cancers: Surgeon Perceptions and Cost-Benefit Trade-Off Analysis

Amish Acharya et al. Ann Surg Oncol. 2017 May.

Abstract

Background: Gastrointestinal cancers constitute the third most common cancers worldwide. Tumor markers have long since been used in the postoperative surveillance of these malignancies; however, the true value in clinical practice remains undetermined.

Objective: This study aimed to evaluate the clinical utility of three tumor markers in colorectal and esophagogastric cancer.

Methods: A systematic review of the literature was undertaken to elicit the sensitivity, specificity, statistical heterogeneity and ability to predict recurrence and metastases for carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9 and CA125. European surgeons were surveyed to assess their current practice and the characteristics of tumor markers they most valued. Data from the included studies and survey were combined in a cost-benefit trade-off analysis to assess which tumor markers are of most use in clinical practice.

Results: Diagnostic sensitivity and specificity were ranked the most desirable characteristics of a tumor marker by those surveyed. Overall, 156 studies were included to inform the cost-benefit trade-off. The cost-benefit trade-off showed that CEA outperformed both CA19-9 and CA125, with lower financial cost and a higher sensitivity, and diagnostic accuracy for metastases at presentation (area under the curve [AUC] 0.70 vs. 0.61 vs. 0.46), as well as similar diagnostic accuracy for recurrence (AUC 0.46 vs. 0.48).

Conclusions: Cost-benefit trade-off analysis identified CEA to be the best performing tumor marker. Further studies should seek to evaluate new tumor markers, with investigation tailored to factors that meet the requirements of practicing clinicians.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Results of the QUADAS-2 evaluation of the included studies with respect to the risk of bias and applicability
Fig. 2
Fig. 2
Survey results detailing the most commonly used tumor markers and the most commonly cited indications in (a, c) colorectal cancer and (b, d) esophagogastric cancer. CEA carcinoembryonic antigen, CA cancer antigen
Fig. 3
Fig. 3
Cost-benefit trade-off for use of the tumor markers in (a) colorectal cancer and (b) esophagogastric cancer. Higher summated cost score represents lower costs, while higher summated benefit score represents higher benefits. CEA carcinoembryonic antigen, CA cancer antigen
See this image and copyright information in PMC

References

    1. National Cancer Institute. SEER stat fact sheets. http://seer.cancer.gov/statfacts/html/colorect.html. Accessed 1 Nov 2015.
    1. Bagaria B, Sood S, Sharma R, Lalwani S. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis) Cancer Biol Med. 2013;10(3):148–157. - PMC - PubMed
    1. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22(4):2311–2316. - PubMed
    1. Yang XQ, Chen C, Wang FB, Peng CW, Li Y. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer. Asian Pac J Cancer Prev. 2011;12(5):1251–1256. - PubMed
    1. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J C Oncol. 2006;24(33):5313–5327. doi: 10.1200/JCO.2006.08.2644. - DOI - PubMed

Publication types

MeSH terms